Q1 2027 Supriya Lifescience Limited Earnings Call Transcript
Key Points
- Revenue grew 31% year-on-year to INR190 crores, driven by strong export demand.
- Backward integration remains a key strength, with 72% of total revenues fully integrated.
- New product launches are progressing well, including two anesthetic liquid inhalation products and a cardiovascular product that has ramped up successfully.
- The company is confident of achieving its FY27 revenue milestone of INR1,000 crores and EBITDA margin guidance of 33%-35%.
- The DSM project has reached a stable state, with pharma validation completed and volumes close to peak levels.
- The company is making good progress on CMO/CDMO opportunities, with a large anesthetic contract close to signing a term sheet.
- The EU audit for the Ambernath facility is scheduled for November, which will open up regulated market opportunities.
- The company has a strong cash reserve of approximately INR150 crores in FDs and mutual funds, with no working capital limits utilized.
- The planned annual maintenance shutdown has been deferred to a phased manner, minimizing impact on Q2 production.
- The company is investing in strengthening internal systems, including SAP implementation and quality management software like TrackWise.
- EBITDA declined 8.1% year-on-year to INR47 crores, with margins at 25%, impacted by temporary cost headwinds.
- Water shortages due to delayed monsoon led to a deferment of sales of around INR35 crores.
- Changes in Maharashtra's solar power policy increased fuel and power costs, impacting EBITDA by INR8 crores.
- PAT declined to INR24 crores from INR35 crores in Q1 FY26, with PAT margin at 12.7%.
- The launch of the contrast media product has been delayed by two quarters due to R&D fine-tuning and raw material cost variations.
- A customs issue related to a psychotropic drug export remains sub judice, with a general manager in judicial custody.
- Inventory levels are on the higher side at INR230-240 crores, which will need to be liquidated over the next few quarters.
- The revenue mix from backward-integrated products declined, impacting EBITDA margins.
- The Patalganga facility is still in early stages, with only boundary wall construction started and API block expected to take around 2.5 years for 40% completion.
- The company faces potential tariff risks in North America, though current exposure is limited.
Ladies and gentlemen, good day, and welcome to the Supriya Lifescience Limited Q1 FY27 Earnings Call. (Operator Instructions)
I now hand over the conference over to Ms. Sneha Salian from EY Investor Relations. Thank you, and over to you, ma'am.
Thank you, Harsh. A warm welcome to all the participants to the Supriya Lifescience Limited Q1 FY27 Earnings Conference Call. The investor presentation and the financial results are available on the company's website and on the stock exchanges. Please note anything said on this call, which reflects our outlook for the future or which can be construed as a forward-looking statement, must be viewed in conjunction with the risks that the company faces. This conference call is being recorded, and the transcript, along with the audio of the same, will be made available on the website of the company as well as on the exchanges.
Please also note that the audio of the conference call is the copyright material of Supriya Lifescience Limited, and it cannot
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
